Opinion|Videos|February 3, 2025
Managing R/R Multiple Myeloma: Current Strategies and Future Directions in Community Practice
Author(s)Amrita Krishnan, MD
The panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized treatment approaches, incorporating novel therapies such as CAR T-cell therapy while carefully monitoring for and managing toxicities through established protocols. Key considerations include implementing systematic toxicity management strategies, maintaining long-term patient monitoring, and staying informed about emerging therapeutic options. The field is evolving with promising novel agents and combination approaches being investigated, particularly for patients who progress after initial treatments.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the key strategies that community-based clinicians can leverage to effectively manage and support patients with R/R multiple myeloma?
- What toxicity mitigation strategies would you consider for patients who receive CAR T for 3L R/R multiple myeloma?
- What recommendations can you share for community providers on long-term monitoring of CAR T in patients with R/R MM?
- What is the future for the treatment of R/R multiple myeloma?
- What novel therapeutic strategies or combination approaches are being investigated for patients with multiple myeloma who progress beyond early lines of therapy?
Advertisement
Related to this article
The UK's OPTIMUM trial showed significant differences with a more aggressive treatment regimen for high-risk newly diagnosed multiple myeloma, based on long-term follow-up.
During a live Case-Based Roundtable event, Brea Lipe, MD, and participants discussed treatment options for an older patient who already received multiple bispecific antibodies for multiple myeloma.
In the pivotal phase 2 QUINTESSENTIAL trial, arlo-cel, a GPRC5D-targeted CAR T-cell therapy, showed favorable overall response rate in patients who had received multiple prior lines including BCMA-targeted therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Daraxonrasib Combo Receives FDA Breakthrough Status in First-Line PDAC
2
Sacituzumab Govitecan Combo Misses PFS End Point in PD-L1–High NSCLC
3
T-DXd Significantly Improves PFS in First-Line HER2-Mutant NSCLC
4
Amivantamab-Chemotherapy Shows Longest OS Reported in EGFR Exon 20 NSCLC
5